Benefits
DashboardNot registered yet? Get a free account.
Sign UpNot registered yet? Get a free account.
Sign Up
You're about to leave our website and go to an external link. Are you sure?
SAI Life Sciences Ltd. provides drug discovery, development, and manufacturing services for pharmaceutical and biotechnology clients.
Sai Life Sciences Limited, is an unlisted public company incorporated on 25 January, 1999. It is classified as a public limited company and is located in Rangareddi, Telangana. It's authorized share capital is INR 25.00 cr and the total paid-up capital is INR 18.88 cr.
Read more
Buy Dashboard using Credits
This action will use 1 of your credits. Are you sure you want to go ahead?
Credits Balance:
0
** All rupee values in INR crores. Based on March 2023 numbers.
37.62%
35.5%
54.55%
2.43%
-6.93%
1.09%
-5.0
-0.22
0.24
0.9
2.71
-0.07
Buy Report or Plans
Company dashboard
Five year financials and ratios
Risk analysis
Interactive charts
All financials
All annual returns
MoA and AoA
Latest financials
Latest annual return
MoA and AoA
Five year financials and ratios
Shareholding and group structure
Litigation and more
Everything in financial report
Peers and financials
* GST not included
** Reports & MCA filings will be based on the latest available financials.
India
(13)
| State | Type | Address |
|---|
Locations on Map
Filter (4)
Severe Risk
Moderate Risk
Low Risk
Read more
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
|---|---|---|---|---|---|
| Sales | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Gross margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Networth | |||||
| Borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Debt to equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Current ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| ROE | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| WC days | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
|---|---|---|---|---|---|
| Equity Capital | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Reserves | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Borrowings + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Long term borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Short term borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Trade payables + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other liabilities + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other non-current liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other current liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Fixed Assets + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Tangible assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| CWIP | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Intangible assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| LT loans and advances | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other non-current assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Current assets + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Inventories | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Trade receivables | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Cash and cash equivalents | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| ST loans and advances | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other current assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
|---|---|---|---|---|---|
| Sales + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Sales growth % | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Expenses + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Cost of goods | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Employee cost | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other costs | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating profit + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating margin % | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other income | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Interest | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Depreciation | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Exceptional items | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Profit before tax | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Tax | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Profit - disc. ops | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net margin % | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
|---|---|---|---|---|---|
| Solvency + | |||||
| Total Debt/Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net Debt/Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total Debt/Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total Assets/Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Liquidity + | |||||
| Current Ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Quick Ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Interest Coverage | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Performance | |||||
| Gross Margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating Margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net Margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Return + | |||||
| Return on Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Pre-tax ROCE | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Return on Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Pre-tax ROIC | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Efficiency + | |||||
| Days Payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days Inventory | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days Receivable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Fixed Asset Turnover | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total Asset Turnover | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Working Capital | |||||
| Cash Conversion Cycle | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Working Capital Days | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
SBICap Trustee Company Limited
No. of Loans: 9
Total Amount : 1,137.7 cr
| Designation | Name | DIN/PAN | Tenure |
|---|---|---|---|
| Whole-time Director | Ranga Raju Kanumuri
Shareholder
|
00043186 | 26 years |
| Managing Director | Krishnamraju Kanumuri
Shareholder
|
00064614 | 14 years |
| CEO | Krishnamraju Kanumuri
Shareholder
|
<HIDDEN> | 8 years |
| Director | Ramesh Ganesh Iyer | 00220759 | 1 years |
| Director | Rajagopal Srirama Tatta
Shareholder
|
00988348 | 18 years |
| CFO | Sivaramakrishnan Chittor
Shareholder
|
<HIDDEN> | 3 years |
| Director | Mitesh Daga | 08189217 | 6 years |
| Director | Suchita Sharma | 10656028 | 1 years |
| CS | Runa Karan
Shareholder
|
<HIDDEN> | 16 years |
| Name | Status | Paid up Capital | Common Directors | Address |
|---|---|---|---|---|
| SAI BIO ASSAY PRIVATE LIMITED |
Strike Off
|
1.0 L | 1 | Telangana |
| SAI ONCOLOGY PRIVATE LIMITED |
Strike Off
|
1.0 L | 1 | Telangana |
| SAI LIFE PHARMA PRIVATE LIMITED |
Active
|
11.5 Cr | 5 | Telangana |
| SAI LIFE DRUGFORM PRIVATE LIMITED |
Under Process of Striking Off
|
1.0 L | 2 | Telangana |
| CONQUEST PHARMA PRIVATE LIMITED |
Amalgamated
|
1.0 L | 1 | Telangana |
| INGENUS PHARMACEUTICALS PRIVATE LIMITED |
Strike Off
|
1.0 L | 1 | Telangana |
| ADVANTIUM PHARMA PRIVATE LIMITED |
Amalgamated
|
79.2 L | 2 | Telangana |
| JRV PROPERTIES LLP |
Active
|
3.0 L | 1 | Telangana |
| PATTANCHERU ENVIRO-TECH LIMITED |
Active
|
2.6 Cr | 1 | Telangana |
| RANMYT TRADING PRIVATE LIMITED |
Active
|
1.0 L | 1 | Telangana |
| SAI QUEST SYN PRIVATE LIMITED |
Active
|
2.0 Cr | 1 | Telangana |
| SOUTH INDIA RESEARCH INSTITUTE PVT LTD |
Active
|
1.5 Cr | 1 | Andhra Pradesh |
| FINANCE INDUSTRY DEVELOPMENT COUNCIL |
Active
|
0.0 | 1 | Maharashtra |
| MAHINDRA BUSINESS & CONSULTING SERVICES PRIVATE LIMITED |
Amalgamated
|
1.0 L | 1 | Maharashtra |
| MAHINDRA SUSTEN PRIVATE LIMITED |
Active
|
390.9 Cr | 1 | Maharashtra |
| NBS INTERNATIONAL LIMITED |
Active
|
44.6 Cr | 1 | Maharashtra |
| MAHINDRA FIRST CHOICE WHEELS LIMITED |
Active
|
94.0 Cr | 1 | Maharashtra |
| TVS CAPITAL FUNDS PRIVATE LIMITED |
Amalgamated
|
27.8 Cr | 1 | Tamil Nadu |
| NOCIL LIMITED |
Active
|
166.9 Cr | 1 | Maharashtra |
| R R KABEL LIMITED |
Active
|
56.4 Cr | 1 | Maharashtra |
| RAM RATNA ELECTRICALS LIMITED |
Amalgamated
|
28.2 Cr | 1 | Gujarat |
| Name | State / Country | Incorporation Year | Paidup Capital |
|---|---|---|---|
| Sai Life Sciences Inc. | United States | - | - |
| SAI LIFE PHARMA PRIVATE LIMITED | Telangana | 2019 | ₹ 11.5 Cr |
| Sai Life Sciences GmbH | Germany | - | - |
| Sai Life Sciences Inc | United States | - | - |
The incorporation date of SAI LIFE SCIENCES LIMITED is 25 January, 1999
The authorized share capital of SAI LIFE SCIENCES LIMITED is INR ₹ 25.0 Cr.
The paid-up capital of SAI LIFE SCIENCES LIMITED is INR ₹ 18.9 Cr.
The registered address of SAI LIFE SCIENCES LIMITED is PLOT NO. DS-7, IKP KNOWLEDGE PARK, TURKAPALLY (V) SHAMEERP ET MANDAL, MEDCHAL-MALKAJGIRI DI ST NA HYDERABAD Rangareddi Telangana - 500078
The CIN number of SAI LIFE SCIENCES LIMITED is U24110TG1999PLC030970.
Expand
Delete
Collapse
See
details
